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Abstract. Background: Estrogen receptor beta (ERβ) belongs
to a large family of nuclear receptors. Recent studies have
suggested that ERβ in contrast to ERα might act as a tumour
suppressor in ovarian cancer (OVCA). Materials and Methods:
Expression of ERβ was detected by immunocytochemistry in 11
OVCA cell lines and by immunohistochemistry in 43 (41 FIGO
stage III) OVCA specimens prepared before chemotherapy and
30 specimens from the same group after chemotherapy.
Cisplatin sensitivity in the 11 cell lines was also analysed.
Results: No significant correlations between cisplatin-
sensitivity and expression of ERβ was found in the cell lines.
In the cases which responded well to chemotherapy (complete
response) ERβ expression at preliminary laparotomy (PL) was
significantly higher (p=0.0004) than in those with progressive
disease. Kaplan-Meier analysis revealed that the patients with
higher ERβ expression (>30% of cells) at PL had an
increased overall survival time and progression-free time
(p=0.00161 and p=0.03255, respectively) than the patients
with lower ERβ espression. Significantly shorter overall
survival time characterized the cases with lower
immunoreactivity score of ERβ expression at secondary
cytoreduction (SCR) (p=0.00346). Conclusion: The loss of ERβ
expression in ovarian tumours may be a feature of malignant
transformation.
Ovarian cancer (OVCA) is one of the most lethal
gynaecological carcinomas worldwide. About 190,000 new
cases and 114,000 deaths from ovarian cancer are estimated to
occur annually. The highest rates are reported in Scandinavia
and Eastern Europe, the USA and Canada (1). Because early-
stage OVCA (FIGO I or II) is generally asymptomatic,
approximately 75% of women present with advanced disease
at diagnosis which is associated with poor prognosis. Survival
is highly dependent on the stage of the disease: 5-year survival
in patients with early-stage is 80-90% compared to 25% for
patients with advanced OVCA (2). 
High serum levels of estrogen have been implicated as a
risk factor for OVCA, but the cellular signal transduction
pathways involved are not completely well known. The
incessant ovulation hypothesis argues that trauma and repair
of ovarian epithelium induced ovulation, contributes to
OVCA development. Ovulatory cycles lead to long-term
exposure of the epithelium to an estrogen-rich environment,
which may promote cellular proliferation, including cyst
formation and possibly malignant transformation (3).
Estrogen receptors, ER alpha (ERα) and ER beta (ERβ)
belong to a large family of nuclear receptors and mediate the
action of estrogens as ligand-dependent transcription factors
(4). The molecular mechanisms of ERβ function in OVCA
are still poorly established, but recent studies have suggested
that ERβ in contrast to ERα might act as a tumour
711
Correspondence to: Agnieszka Halon, Department of
Pathomorphology, Wroclaw Medical University, Marcinkowskiego
1, 50-368 Wroclaw, Poland. Tel: +48 717841240, Fax: +48
717840057, e-mail: ahalon2@gmail.com
Key Words: Estrogen receptor beta, ovarian cancer, prognostic
factor, immunohistochemistry, cisplatin.
ANTICANCER RESEARCH 31: 711-718 (2011)
Loss of Estrogen Receptor Beta Expression Correlates with
Shorter Overall Survival and Lack of Clinical Response 
to Chemotherapy in Ovarian Cancer Patients
AGNIESZKA HALON1, EWA NOWAK-MARKWITZ2, ADAM MACIEJCZYK3, MAREK PUDELKO3,
TSERENCHUNT GANSUKH4, BALÁZS GYÖRFFY5,6, PIOTR DONIZY1, DAWID MURAWA7, 
RAFAL MATKOWSKI3,8, MAREK SPACZYNSKI2, HERMANN LAGE6 and PAWEL SUROWIAK3,6,9
Departments of 1Pathomorphology, 8Oncology, and 9Histology and Embryology, 
Wroclaw Medical University, Wroclaw, Poland;
2Department of Obstetrics and Gynaecology, University School of Medicine, Poznan, Poland;
3Lower Silesian Oncology Centre, Wroclaw, Poland;
71st. Department of Surgical Oncology, Wielkopolska Cancer Center, Poznan, Poland;
4Medical Research Institute of Mongolia, Bayangol duureg, Ulan Bator, Mongolia;
5Semmelweis University Budapest, First. Department of Pediatrics, Budapest, Hungary;
6Charité Campus Mitte, Institute of Pathology, Berlin, Germany
0250-7005/2011 $2.00+.40
suppressor in OVCA (4, 5). Preliminary studies have
revealed that ERβ levels, both protein and mRNA in OVCA
decline relative to levels in the normal ovary (4, 6-8). Chan
et al. (9), demonstrated that the immunoreactivity score of
ERβ expression was significantly higher in normal tissue
compared with malignant and its expression was a significant
good predictor for disease-free survival and overall survival.
Furthermore, the absence of ERβ in OVCA might be a
feature of malignant transformation (9). 
From the 1970s, the ERs has evolved to be the most
effective target for breast and ovarian cancer therapy.
Interactions between estradiol (E2) and ERs can be
effectively blocked using a variety of agents, such as
selective ER modulators (SERMs). Tamoxifen and raloxifen
as a leading SERMs, are competitive inhibitors of E2 at the
ERs and display distinct effects depending on the tissues
(10). Only 15-18% of ER-positive OVCA initially respond
to anti estrogen treatment based on blocking of estrogen-ER
binding, in contrast to effective treatment of about 50% of
ER-positive breast carcinomas (11). The most common
mechanism of antiestrogen resistance is the absence of ER.
From the previous data, the role of tamoxifen in OVCA has
not been properly established, although some authors have
suggested that combined therapy with cisplatin and
tamoxifen might reduced cisplatin resistance (12, 13).
The significance of ERβ expression in ovarian
carcinogenesis and its impact on growth and survival of
OVCA cells is still controversial. In this study, the
expression of ERβ, in malignant epithelial ovarian tumours,
and OVCA cell lines was investigated. Because cisplatin
resistance is a major obstacle in the treatment of OVCA,
analysis of cisplatin sensitivity in 11 OVCA cell lines was
also performed. 
Materials and Methods
Cell culture. The cisplatin-resistant cell line, A2780RCIS, was
derived from the OVCA cell line, A2780 (14). The human OVCA
cell lines CAOV-3, EFO 21, EFO 27, ES-2, Mdah 2774, OAW 42,
OVCAR-3, PA-1 and SKOV-3 were kindly provided by Dr. Carsten
Denkert (Institute of Pathology, Charité, Berlin, Germany). The
human OVCA cells were grown in Leibovitz L-15 medium
(Biowhittaker, Walkersville, MD, USA) supplemented with 10%
fetal calf serum (FCS) (GIBCO/BRL, Grand Island, NY, USA), 1
mM L-glutamine, 6.25 mg/l fetuin, 80 IE/l insulin, 2.5 mg/ml
transferrin, 0.5 g/l glucose, 1.1 g/l NaHCO3, 1% minimal essential
vitamins and 20,000 kIE/l trasylol in a humidified atmosphere of
5% CO2 at 37˚C as described previously (14-17). In order to ensure
maintenance of the cisplatin-resistant phenotype of the A2780RCIS
cells, the medium was supplemented with 10 Ag/mL of cisplatin
(33.3 μmol/L; GRY-Pharm, Kirchzarten, Germany).
Cell proliferation assay. Chemoresistance was tested using a
proliferation assay based on sulphorhodamine B (SRB) staining as
described previously (18). Briefly, 800 cells per well were seeded
in 96-well plates in triplicate. After 24 h attachment, cisplatin was
added in dilution series for a 5-day incubation, before SRB staining
was performed. Incubation with cisplatin was terminated by
replacing the medium with 10% trichloroacetic acid, followed by
incubation at 4˚C for 1 h. Subsequently, the plates were washed five
times with water and stained by adding 100 μl 0.4% SRB (Sigma,
St. Louis, MO,USA) in 1% acetic acid for 10 min at room
temperature. Washing the plates five times with 1% acetic acid
eliminated unbound dye. After air-drying and re-solubization of the
protein bound dye in 10 mM Tris-HCl (pH=8.0) absorbance was
read at 562 nm in an Elisa-Reader (EL 340 Microplate Bio Kinetics
Reader, BIO-TEK Instruments, Winooski, VT, USA). The
measurements were performed in triplicates in three independent
experiments. The IC50-values were calculated from three
independent experiments for each cell line.
Patients. Immunohistochemical examination was performed
retrospectively on tissue samples taken for routine diagnostic
purposes. Forty three patients who had undergone surgery in 1999-
2002 due to OVCA in the Department of Gynaecology and
Obstetrics, University Medical School in Poznań, Poland were
included in the study. The cases were selected based on availability
of tissue and were not stratified for known preoperative or
pathological prognostic factors. The study was approved by an
Institutional Review Board (IRB) and the patients gave their
informed consent before their inclusion into the study. Following the
primary laparotomy (PL) all the patients were subjected to
chemotherapy using cisplatin-based schemes (Table I). Thirty six
patients from the same group were also subjected to secondary
cytoreduction (SCR). In seven cases no second-look procedure was
performed due to advancement of the disease. In six cases no tumour
cells were detected in the material originating from the second-look
procedure. The patients were monitored by periodic medical check-
ups, ultrasonographic, radiological and cancer antigen 125 (CA-125)
serum levels examinations. During the 52 months follow-up period,
22 patients (51%) had recurrent disease and 13 patients (30%) died
of the disease. The mean progression-free survival time was 16.9
months (range 0 to 52 months), while the mean overall survival time
was 24.6 months (range 6 to 52 months). Only the one stage I and
one stage II patient achieved optimal cytoreduction.
Tissue samples were fixed in 10% buffered formalin and embedded
in paraffin. In each case, hematoxylin and eosin stained preparations
were subjected to histopathological evaluation by two pathologists.
The stage of the tumours was assessed according to the International
Federation of Gynaecology and Obstetrics (19). Tumours were graded
according to the Silverberg grading system (20). 
Immunohistochemistry. Formalin-fixed, paraffin embedded tissue
was freshly cut (4 μm). The sections were mounted on Superfrost
slides (Menzel Gläser, Braunschweig, Germany), dewaxed with
xylene and gradually hydrated. Activity of endogenous peroxidase
was blocked by 5 min exposure to 3% H2O2. All the sections were
boiled for 15 min at 250W in Antigen Retrieval Solution
(DakoCytomation, Glostrup, Denmark). Then, immunohisto-
chemical reactions were performed using the mouse mAb PPG5/10
(DakoCytomation) directed against ERβ 1 (dilution 1:50 in
Antibody Diluent, Background Reducing (DakoCytomation) 1 h at
20˚C). Each reaction was accompanied by a negative control using
Primary Mouse Negative Control (DakoCytomation). Subsequent
incubations involved biotinylated antibodies (15 min, room
temperature) and streptavidin-biotinylated peroxidase complex (15
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min, room temperature) (Dako Detection System, LSAB+ and
horseradish peroxidase, HRP, DakoCytomation). Diaminobenzidine
(DAB, DakoCytomation) was used as a chromogen (7 min, at room
temperature). All the sections were counterstained with Meyer’s
hematoxylin. In this study, the Ki67 (21), and p53 (22) expression
data, which had been investigated previously on the same group of
patients (23), were reused. 
Immunocytochemistry. Immunostaining of ERβ was performed in
all the cell lines. The cells were grown on microscope slides and
fixed in on ice-cold methanol-acetone mixture (1:1) for 10 min.
After re-hydration, the immunostaining reaction was performed in
triplicate as described above. Furthermore, immunostaining of Ki67
was conducted for all the cell lines with mouse mAB against Ki67
(clone MIB-1; dilution 1:100 in Antibody Diluent, Background
Reducing, DakoCytomation, 1 h at 20˚C).
Evaluation of reaction intensity. The intensity of the
immunohistochemical and immunocytochemical reactions were
estimated independently by two pathologists. Assessment of staining
was “blinded” to sample details. In doubtful cases a re-evaluation
was performed using a double-headed microscope and staining was
discussed until a consensus was achieved. Immunostaining reactions
of p53 and Ki67 were evaluated using percentage of positive cells
score. The expression of ERβ was graded using a semiquantitative
scoring scale based on percentage of reactive cells (no
staining=score 0, <10%=score 1, 10-30%=score 2, >30%=score 3).
Consequently, four possible products (0, 1, 2, 3) were obtained. 
Statistical analysis. Statistical analysis of the results took advantage
of Statistica 98 PL software (Statsoft, Krakow, Poland), SPSS
software (release 10.0; SPSS Inc., Chicago, IL, USA) and Microsoft
Office Excel 2007 (Microsoft Corporation, Redmond, WA, USA).
The employed tests included Mann-Whitney U-test, Spearman’s rank
correlation, Chi-square and Kruskal-Wallis test. Kaplan-Meier
statistics and log-rank tests were performed to estimate the
significance of differences in survival times. The length of
progression-free survival was defined as the time between the primary
surgical treatment and diagnosis of a recurrent tumour or death. 
Results
Cisplatin-sensitivity of cell lines. The sensitivity of the
various human OVCA cell lines against treatment with
cisplatin was determined by the assessment of IC50 values
(Table II). The most sensitive cell line, PA-1, exhibited an
IC50 of 0.75 μM, and the most cisplatin-resistant cell line,
A2780RCIS, demonstrated an IC50 of 98.98 μM. 
ERβ immunostaining in cell lines. Strong nuclear ERβ
expression (score 3) was shown in the EFO 21 cells (Figure
1A). Interestingly, the immunocytochemical experiments
showed that ERβ could also be detected in the cytoplasm of
the OVCAR-3 and ES-2 cells (score 2 and 1, respectively).
The other cell lines were ERβ negative (Figure 1B, EFO 27
cells). No significant correlations were found between
cisplatin-sensitivity and the expression of ERβ in the OVCA
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Table I. Patient and tumour characteristics. 
Patient and tumour characteristics Nc %
All patients 43 100
Age (mean 51)a
≤50 20 47
50-60 16 37
>60 7 16
Gradea
1 7 16
2 18 42
3 18 42
FIGOa
I 1 2
II 1 2
III 41 95
Histologya
Serous 37 86
Endometrioid 3 7
Other 3 7
Clinical responseb
Complete response 16 37
Stable disease 5 12
Progressive disease 22 51
Chemotherapy (in total)
Cisplatin/Paclitaxel 31 72
Cisplatin/Cyclophosphamide/Adriblastin 6 14
Cisplatin/Cyclophosphamide/Paclitaxel 3 7
Cisplatin/Cyclophosphamide/Paclitaxel/Adriblastin 2 5
Carboplatin/Paclitaxel 1 2
aData are given for the first operation/diagnosis implemented.
bAccording to RECIST 1.0 (Response Evaluation Criteria in Solid
Tumours) (29). cDifferences in the sum to 100 % in groups are due to
rounding.
Table II. Chemosensitivity to cisplatin (IC50 value) and immunoreactivity
score of ERβ and Ki67 expression in human ovarian carcinoma cell
lines. 
Cell line ERβ ERβ Ki67 Cisplatin
expression expression expressiona IC50 
nuclear cytoplasmic (μM)
A2780P 0 0 20 23.87
A2780RCIS 0 0 20 98.98
CAOV-3 0 0 60 1.92
EFO 21 3 0 10 5.08
EFO 27 0 0 15 2.25
ES-2 0 1 80 7.64
Mdah 2774 0 0 90 6.36
OAW 42 0 0 5 5.49
OVCAR-3 0 2 20 1.88
PA-1 0 0 80 0.75
SKOV-3 0 0 75 18.85
aPercentage of positive cells.
cell lines. Additionally, statistical analysis did not reveal any
correlations between the expression of ERβ and Ki67.
Figures 2A and 2B present the expression of Ki67 in Mdah
2774 and OVCAR-3 cells, respectively.
ERβ expression and clinicopathological and immunohisto-
chemical parameters. Immunoreactivity of variable intensity was
obtained in the individual OVCA cases (Figure 1C and D). At
the first stage of statistical analysis of relationships between ERβ
expression and clinicopathological parameters of the patients, the
Kruskal-Wallis test was used. The relationship between the
percentage of positive ERβ cells and the histological type of the
tumour, the grade and the clinical response to chemotherapy was
examined (Figure 3, Table III). In the cases which responded
well to chemotherapy (complete response) based on cisplatin the
immunoreactivity score of ERβ expression at PL was
significantly higher (p=0.0004) than in patients with progressive
disease (Figure 4). Statistical analysis did not reveal any
significant correlations between ERβ expression and Ki67 and
p53 percentage of positive cells (Table III). 
In the Kaplan-Meier analysis overall survival time and
progression-free time were compared between cases showing
lower (0-30%) or higher (31-100% of positive cells)
immunoreactivity score of ERβ expression at PL and SCR.
The patients with higher ERβ expression at PL had an
increased overall survival time (Figure 5A) and an increased
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Figure 1. Immunohistochemical localization of ERβ expression in EFO 21 cells (A., ×200; hematoxylin), EFO 27 cells (B., ×200; hematoxylin) and
in ovarian cancer tissue (C., ×200, D., ×200; hematoxylin).
Table III. Correlation between estrogen receptor beta expression and
various clinicopathologic and immunohistochemical parameters. 
Characteristics p-Value
Histological typea 0.6881
Gradea 0.5379
Clinical responsea 0.0004
Ageb 0.7932
Ki67b 0.2742
p53b 0.1647
CA-125b 0.7485
aANOVA rang Kruskal-Wallis. bSpearman’s rank correlation.
progression-free time (Figure 5B) than the patients with
lower ERβ expression. The analysis also demonstrated that
significantly shorter overall survival time characterized the
cases with lower immunoreactivity score of ERβ expression
at SCR (Figure 6A). No significant differences in
progression-free time between the patients with lower and
higher ERβ expression at SCR was observed (Figure 6B).
Since no significant relationships between the studied
clinicopathological parameters (age, histology, grade, CA-
125 at PL level) and overall survival and progression-free
time was found with univariate analysis (p>0.05), a
multivariate analysis was not performed. Since 95% of the
patients were in stage FIGO III, relationships between stage
and survival data were not investigated. 
Discussion
The most sensitive OVCA cell line, PA-1, exhibited an IC50
of 0.75 μM and the most cisplatin-resistant cell line,
A2780RCIS, demonstrated an IC50 of 98.98 μM. However
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Figure 2. Immunocytochemical localization of Ki67 expression in Mdah 2774
cells (A., ×200; hematoxylin) and OVCAR-3 cells (B., ×400; hematoxylin).
Figure 3. Expression of ERβ at preliminary laparotomy in relation to
clinical and pathological data of the patients. CR: complete response,
SD: stable disease, PD: progressive disease.
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Figure 4. Expression of ERβ and clinical response to chemotherapy.
Figure 5. Kaplan-Meier curves for survival in relation to ERβ
expression at preliminary laparotomy. 
Figure 6. Kaplan-Meier curves for survival in relation to ERβ
expression at secondary cytoreduction. 
no significant correlations between cisplatin-sensitivity and
ERβ expression were found in the cell lines, nor were any
correlations between expression of ERβ and Ki67 found.
Treeck et al. (24) studied the role of ERβ1 and two of its
splice variants (ERβ-δ125, ERβ-δ1256) in the regulation of
gene expression, apoptosis, cellular proliferation and
migration of SKOV-3 OVCA cells and demonstrated that
ERβ1 expression displayed multiple antitumoral effects.
The expression of ERβ in the tissue samples from OVCA
patients was not correlated with the histopathological
parameters, such as histological type and cancer grade. In the
cases which responded well to chemotherapy based on
cisplatin the immunoreactivity score of ERβ expression at
PL was significantly higher (p=0.0004) than in the patients
with progressive disease. Moreover, Kaplan-Meier analysis
revealed that the patients with higher ERβ expression at PL
had an increased overall survival time (p=0.00161) and an
increased progression-free time (p=0.03255) than the
patients with lower ERβ expression. Significantly shorter
overall survival time also characterized the cases with lower
of ERβ expression at SCR (p=0.00346).
The loss of ERβ expression in ovarian tumours may be a
feature of malignant transformation. Chan et al. (9) in
addition to showing that ERβ expression was significantly
higher in normal ovary than malignant tissues, also showed
significant correlations between the stage of disease and level
of ERβ expression (higher in stage I than stage II-IV).
Multivariable analysis confirmed the role of ERβ in ovarian
carcinogenesis, because its higher expression was found to
be connected with longer disease-free survival as well as
overall survival as confirmed in present study. 
Several earlier studies have also investigated the status of
ER status in relation to survival (25, 26). Interestingly,
Fujimoto et al. (26) found that patients with a low or high
ratio of ERα to ERβ had a significantly worse prognosis than
patients with a more equal ratio. 
In metastatic OVCA cells ERβ expression is often lost
(27) however, its role in ovarian carcinogenesis is still
unclear. EMT (epithelial-mesenchymal transition), a highly
conserved process in which epithelial cells undergo a
phenotypic switch to form mesenchymal-like cells, involves
the loss of polarity and intracellular adhesion. These
molecular and structural alterations are thought to allow
dynamic cellular migration and the development of local
and distant metastases. Park et al. identified ERβ
overexpression as an important factor in the inhibition of
prometastatic effects connected with the promotion of EMT
in OVCA cells (28). Their results suggested that ERβ may
have a function as a negative modulator of ERα in
carcinogenesis of the ovary and the development of
metastatic potential. 
Overall, greater understanding of the role of ERβ
expression in ovarian cancer may help to develop and
explore further the potential of hormonal therapy in ovarian
tumours. Future studies on ERβ are needed to determine
fully the clinicopathological implications of ERβ in ovarian
carcinogenesis. 
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